University of California, San Diego

ucsd.edu

Total trials

955

Active

248

Phase 3

39

Total enrollment

433,673

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 40 of 113 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
vancomycin2
Multimodal Pain Management1
Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]1
single injection nerve block1
Dupilumab1
Benralizumab1
0.2% ropivacaine local anesthetic continuous erector spinae plane block1
0.2% ropivacaine local anesthetic superficially taped continuous erector spinae plane block1
Spinal Morphine1
Experimental continuous peripheral nerve blocks1
Control continuous peripheral nerve blocks1
Testosterone Cypionate 50 milligrams per millileter (mg/mL) Injectable Solution1
Continuous Infusion of ropivacaine 0.2%1
Titratable Automated Intermittent Boluses of ropivacaine 0.2%1
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL1
Popliteal nerve block including liposomal bupivacaine1
Adductor canal nerve block including liposomal bupivacaine1
Continuous popliteal nerve block with normal saline1
Popliteal nerve block with exclusively unencapsulated bupivacaine1
Adductor canal nerve block with exclusively unencapsulated bupivacaine1
Continuous popliteal nerve block with unencapsulated bupivacaine1
Tranexamic Acid1
Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg1
Emtricitabine Tenofovir Alafenamide 200/25 mg1
suzetrigine1
Omeprazole 40 MG1
Clevidipine1
Lactated Ringers, Intravenous1
PharmaNord Bio-Quinone Active CoQ10 Gold 100mg1
PharmaNord Placebo1
Sotagliflozin Low Dose1
Sotagliflozin High Dose1
Cannabidiol oral solution1
Acetazolamide6
Medi-TBS2
THC2
Eszopiclone4
Rituximab4
REMD-4773
Nivolumab3
73 more active programs hidden

Next readouts

  • 2021-11-30
  • 2023-05-01
  • 2023-12-31
  • 2024-01-31
  • 2024-06-30
  • 2024-07-17
  • 2024-12
  • 2024-12-31
  • 2025-02-28
  • 2025-07-22

Top conditions

  • Obesity34
  • Obstructive Sleep Apnea26
  • Schizophrenia24
  • Depression24
  • Breast Cancer20
  • HIV19
  • Anorexia Nervosa18
  • Contraception18

Frequently asked questions about University of California, San Diego

How many clinical trials does University of California, San Diego have on ClinicalTrials.gov?
University of California, San Diego is listed as the lead sponsor on 955 clinical trials in ClinicalTrials.gov, 248 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of California, San Diego's trials are in Phase 3?
39 of University of California, San Diego's trials are in Phase 3, spread across 113 active drug programs.
What therapeutic areas does University of California, San Diego focus on?
University of California, San Diego's most-studied conditions on ClinicalTrials.gov are Obesity, Obstructive Sleep Apnea, Schizophrenia, Depression, Breast Cancer.
When are University of California, San Diego's next clinical trial readouts?
University of California, San Diego has 10 upcoming primary-completion readouts tracked here; the soonest is “Directed Use of REmote Patient Management System AMia to Achieve Prescribed Dry Weight”, expected around 2021-11-30.